Lenz Therapeutics Inc (LENZ)

May 04, 2025

JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 04, 2025

May 02, 2025

Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 02, 2025

May 01, 2025

Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 01, 2025

Apr 30, 2025

LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq

Apr 30, 2025

Apr 30, 2025

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times

Apr 30, 2025

Apr 30, 2025

Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan

Apr 30, 2025

Apr 28, 2025

Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail

Apr 28, 2025

Apr 26, 2025

ProfittoPath - TradingView

Apr 26, 2025

Apr 25, 2025

LENZ Therapeutics Inc (LENZ)’s stock chart: A technical perspective - uspostnews.com

Apr 25, 2025

Apr 24, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World

Apr 24, 2025

Apr 22, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Alliancebernstein L.P. - Defense World

Apr 22, 2025

Apr 19, 2025

LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025

Apr 18, 2025

Before Buying LENZ Therapeutics Inc (NASDAQ: LENZ) Stock, Read This First - Stocksregister

Apr 18, 2025

Apr 15, 2025

LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper Sandler - Defense World

Apr 15, 2025

Apr 14, 2025

Form 424B3 LENZ Therapeutics, Inc. - StreetInsider

Apr 14, 2025

Apr 14, 2025

Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com Australia

Apr 14, 2025

Apr 14, 2025

Piper Sandler raises LENZ Therapeutics stock to Overweight By Investing.com - Investing.com Canada

Apr 14, 2025

Apr 14, 2025

Piper Sandler Projects Strong Growth for Lenz Therapeutics (LENZ) with LNZ100 | ABBV Stock News - GuruFocus

Apr 14, 2025

Apr 14, 2025

Lenz Therapeutics assumed with an Overweight at Piper Sandler - TipRanks

Apr 14, 2025

Apr 14, 2025

Wellington Management Group LLP Has $815,000 Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Apr 14, 2025

Apr 14, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Vanguard Group Inc. - Defense World

Apr 14, 2025

Apr 13, 2025

KLP Kapitalforvaltning AS Makes New $46,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Apr 13, 2025

Apr 12, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Brokerages - Defense World

Apr 12, 2025

Apr 11, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World

Apr 11, 2025

Apr 11, 2025

8,485 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Raymond James Financial Inc. - Defense World

Apr 11, 2025

Apr 07, 2025

LENZ Therapeutics: Freedom From Reading Glasses (NASDAQ:LENZ) - Seeking Alpha

Apr 07, 2025

Apr 04, 2025

Presbyopia Treatment Market Size in 7MM is expected to grow at - openPR.com

Apr 04, 2025

Mar 31, 2025

18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National Bank - Defense World

Mar 31, 2025

Mar 31, 2025

Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

Mar 31, 2025

Mar 27, 2025

LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha

Mar 27, 2025

Mar 27, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Mar 27, 2025

Mar 26, 2025

Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Mar 26, 2025

Mar 24, 2025

Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World

Mar 24, 2025

Mar 24, 2025

What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World

Mar 24, 2025

Mar 24, 2025

William Blair Issues Negative Outlook for LENZ Earnings - Defense World

Mar 24, 2025

Mar 23, 2025

LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World

Mar 23, 2025

Mar 22, 2025

Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World

Mar 22, 2025

Mar 22, 2025

What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World

Mar 22, 2025

Mar 21, 2025

Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks

Mar 21, 2025

Mar 21, 2025

Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks

Mar 21, 2025

Mar 21, 2025

Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World

Mar 21, 2025

Mar 20, 2025

Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com

Mar 20, 2025

Mar 20, 2025

Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView

Mar 20, 2025

Mar 20, 2025

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times

Mar 20, 2025

Mar 19, 2025

Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN

Mar 19, 2025

Mar 19, 2025

Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com India

Mar 19, 2025

Mar 19, 2025

Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive By Investing.com - Investing.com UK

Mar 19, 2025

Mar 19, 2025

LENZ Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 19, 2025